Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > Spectral on Linkedin Today
View:
Post by TechOne on Dec 06, 2024 3:42pm

Spectral on Linkedin Today

Understanding Endotoxin Detection: EAA™ vs. LAL Assay

The Endotoxin Activity Assay (EAA™) and the Limulus Amebocyte Lysate (LAL) assay are two prominent methods for detecting endotoxins, but their methodologies and applications vary significantly. Here's a breakdown:

Methodology

• EAA™: Measures neutrophil activation, rapidly assessing endotoxin levels in whole blood.
• LAL Assay: Utilizes lysate from horseshoe crab blood, detecting endotoxin through coagulation reactions.

Sensitivity and Specificity

• EAA™: Optimized for low endotoxin concentrations, effective in clinical scenarios, and has been correlated with patient outcomes.
• LAL Assay: a quantitative test for endotoxin measurement in crystalloid solutions, but cannot accurately detect endotoxin in whole blood or plasma.

In summary:

• The EAA™ is ideal for semi-quantitative analysis of endotoxins in whole blood, suitable for clinical use.
• The LAL Assay is best for precise endotoxin detection in crystalloid solutions but not appropriate for blood-based samples.

Understanding these differences can help in choosing the right assay for specific research or clinical applications. Learn more: https://buff.ly/3ZyGoYJ
Comment by PezDalatoYou on Dec 07, 2024 1:36pm
I find it interesting that Spectral continues to post in a positive manner on LinkedIn. Given that they already know the direction of the trial outcome, I think it would be a fraud to continue to publicly post this stuff if the trial is headed in a negative direction. Although my trust in the management team doesn't totally dismiss a fraud, an intentional and obvious fraud would be unlikely, I ...more  
Comment by Geery on Dec 07, 2024 2:08pm
Pez, I am with you on both parts of your comment. Positive posts feel good, but like you, in my many years of Spectral share ownership I have never had any trust in mgmt.  Maybe I missed something over the years but I can't think of any moments/updates/anniuncements/etc., that made me think different.  Is this the norm for tiny cap companies going through these trials?  ...more  
Comment by Spamme54321 on Dec 07, 2024 3:27pm
You are right not to trust management. All company management are self serving. They dont care about the shareholders just like we dont care about them. We are all here to make a profit.
Comment by gebremeskel on Dec 07, 2024 7:11pm
When a company is in the last stages of its' existence and the company's managers have built up substantial personal share counts in anticipation of the endgame, how do the interests of managers diverge from the interests of any other shareholders?
Comment by mercedesman on Dec 07, 2024 8:00pm
Hey G  You're are correct... the interests of Mgt. and minority shareholders are almost  and finally fully aligned.  Perhaps after one more final option/ PSU/ DS/U warrant /etc grant they will be 100% aligned ?  The ball is in CG's court, at least on the first issue of taking ownership of Vantive which has to be weeks, or worst case, down to a month or so away  ...more  
Comment by Spamme54321 on Dec 07, 2024 11:01pm
I am just saying if they could find a way to screw over the shareholders to make a quick buck for themselves 100% they would do it. Not saying we currently don't have the same goals.
Comment by oilandgasman on Dec 08, 2024 11:12am
My problem with management is they’ve thought they were holding aces a few times and flipped 2’s when called.   The pump and October 2016 result disappointment still ring here. 
Comment by hmmmmmmmm on Dec 08, 2024 3:57pm
Interesting. I'm not on LikedIn but curious- are they posting statements re: the Tigris trial? Most of their posts that have been reposted here have been EAA related. If they are making "exceeding expec†ation" esq claims on LikedIn that would be telling..
Comment by BlueJays9293 on Dec 08, 2024 8:05pm
Didn't 60 Minutes do a whole thing about how Linkedin was maybe a whole weird Networking Cult of mutants failing upwards and glad handing each other??? Or was it 60 Minutes Australia, I forget. Maybe it was just a dream, of a world that was a little more anti-social media, who knows. Either way, we'll be getting some more info on things in the coming week. 
Comment by Spamme54321 on Dec 09, 2024 5:27pm
BJ is confusing LinkedIn with the cult of mutant pumpers on this board LOL. And 'glad handing each other' is what the pumpers here do best!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities